Build an Intraocular Lens and Anti-VEGF Injectable Supplier

1. 1

   Choose the premium product line

   The two highest-value lines are advanced-technology intraocular lenses (multifocal, extended-depth-of-focus, toric, and premium presbyopia-correcting IOLs that patients pay out of pocket to upgrade to) and anti-VEGF intravitreal injection drugs (used repeatedly for macular degeneration and diabetic eye disease). Each is a different business with different science, regulation, and economics. Biosimilar anti-VEGF agents are a distinct opportunity from novel drug development. Pick one line and own it.

2. 2

   Fund the clinical and regulatory pathway

   Premium IOLs are Class III devices and anti-VEGF drugs are biologics or pharmaceuticals, both requiring extensive clinical testing and FDA approval over multiple years and large capital. Time to first dollar is measured in years. The regulatory pathway is the single biggest determinant of cost and timeline, so the strategy has to be set early with expert regulatory input. Undercapitalization ends most entrants before approval.

3. 3

   Build the manufacturing and quality system

   Manufacturing implantable lenses or injectable drugs demands rigorous quality systems (device QSR / ISO 13485 for IOLs, GMP for injectables), sterility, and traceability. These are patient-safety-critical products where a quality failure is catastrophic. Whether you build or contract manufacturing, quality is the core competency, not a support function. Design it in parallel with the product.

4. 4

   Generate the surgeon-facing clinical evidence

   Surgeons adopt premium IOLs and injectables based on outcomes, safety data, and peer experience, so published clinical evidence and key-opinion-leader support drive adoption more than any sales pitch. Premium IOL patients also pay cash for the upgrade, so patient-facing value and surgeon confidence both matter. Build the evidence base deliberately. It is the real marketing in surgical products.

5. 5

   Reach practices and consolidating platforms

   Buyers are ophthalmology practices, surgery centers, and increasingly the PE-backed platforms actively expanding premium lines to raise revenue per patient. Selling into platforms means one relationship can cover many sites, which is a distribution advantage worth pursuing. Distribution runs through specialized sales forces and distributors, with reimbursement pathways for injectables shaping demand. Align your commercial strategy with where consolidation is concentrating buying power.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.